Vladimir Kartashev1, Matthias Döring2, Leonardo Nieto3, Eleda Coletta4, Rolf Kaiser5, Saleta Sierra6. 1. Department of Infectious Diseases, Rostov State Medical University, 344022 Rostov on the Don, Russia. 2. Computational Biology and Applied Algorithmics, Max Planck Institute for Informatics, 66123 Saarbrücken, Germany; Saarbrücken Graduate School of Computer Science, Saarland University, 66123 Saarbrücken, Germany. 3. Liver Pathology Lab, Biochemistry and Microbiology Departments, University Hospital Vall d'Hebron, Universitat Autònoma de Barcelona, CIBERehd, 08035 Barcelona, Spain. 4. Microbiology and Immunology Unit, Valladolid University Hospital, 47005 Valladolid, Spain. 5. Cologne-Bonn DZIF Partner Site, Institute of Virology, University of Cologne, 50935 Cologne, Germany. Electronic address: Rolf.kaiser@uk-koeln.de. 6. Cologne-Bonn DZIF Partner Site, Institute of Virology, University of Cologne, 50935 Cologne, Germany.
Abstract
BACKGROUND: HCV affects 185 million people worldwide and leads to death and morbidities. HCV has a high genetic diversity and is classified into seven genotypes and 67 subtypes. Novel anti-HCV drugs (Direct-Acting-Antivirals) eligibility, resistance and cure rates depend on HCV geno/subtype (GT). OBJECTIVES: Analysis of epidemiological information and viral GT from patients undergoing viral genotyping in 2011-2015. STUDY DESIGN: Anonymized information from 52 centers was analyzed retrospectively. RESULTS: 37,839 samples were included in the study. We show that the GT distribution is similar throughout Western European countries, with some local differences. Here GTs 1 and 2 prevalences are lower and of GT4 higher than in all previous reports. Israel has a unique GT pattern and in South Russia the GT proportions are more similar to Asia. GTs 5 and 6 were detected in very low proportions. Three cases of the recombinant genotype P were reported in Munich (Germany). In addition, we observed that GT proportion was dependant on patientś gender, age and transmission route: GTs 1b and 2 were significantly more common in female, older, nosocomially-infected patients, while GTs 1a, 3 and 4 were more frequent in male, younger patients infected by tattooing, drug consume, and/or sexual practices. In infections acquired by drug consume, GTs 1a (35.0%) and 3 (28.1%) prevailed. In infections related to sexual practices lower proportion of GT3 (14.0%) and higher of GT4 (20.2%) were detected. GT4 was mostly abundant in MSM (29.6%). HIV coinfection was significantly associated with higher proportions GTs 1a and 4 (42.5% and 19.3%, respectively). CONCLUSION: Genotype prevalence evolves and correlates to epidemiological factors. Continuous surveillance is necessary to better assess hepatitis C infection in Europe and to take appropriate actions.
BACKGROUND: HCV affects 185 million people worldwide and leads to death and morbidities. HCV has a high genetic diversity and is classified into seven genotypes and 67 subtypes. Novel anti-HCV drugs (Direct-Acting-Antivirals) eligibility, resistance and cure rates depend on HCV geno/subtype (GT). OBJECTIVES: Analysis of epidemiological information and viral GT from patients undergoing viral genotyping in 2011-2015. STUDY DESIGN: Anonymized information from 52 centers was analyzed retrospectively. RESULTS: 37,839 samples were included in the study. We show that the GT distribution is similar throughout Western European countries, with some local differences. Here GTs 1 and 2 prevalences are lower and of GT4 higher than in all previous reports. Israel has a unique GT pattern and in South Russia the GT proportions are more similar to Asia. GTs 5 and 6 were detected in very low proportions. Three cases of the recombinant genotype P were reported in Munich (Germany). In addition, we observed that GT proportion was dependant on patientś gender, age and transmission route: GTs 1b and 2 were significantly more common in female, older, nosocomially-infectedpatients, while GTs 1a, 3 and 4 were more frequent in male, younger patients infected by tattooing, drug consume, and/or sexual practices. In infections acquired by drug consume, GTs 1a (35.0%) and 3 (28.1%) prevailed. In infections related to sexual practices lower proportion of GT3 (14.0%) and higher of GT4 (20.2%) were detected. GT4 was mostly abundant in MSM (29.6%). HIV coinfection was significantly associated with higher proportions GTs 1a and 4 (42.5% and 19.3%, respectively). CONCLUSION: Genotype prevalence evolves and correlates to epidemiological factors. Continuous surveillance is necessary to better assess hepatitis C infection in Europe and to take appropriate actions.
Authors: Roman Chlibek; Jan Smetana; Renata Sosovickova; Peter Gal; Petr Dite; Vlasta Stepanova; Lenka Pliskova; Stanislav Plisek Journal: PLoS One Date: 2017-04-13 Impact factor: 3.240
Authors: V S Kichatova; K K Kyuregyan; N V Soboleva; A A Karlsen; O V Isaeva; M G Isaguliants; M I Mikhailov Journal: J Immunol Res Date: 2018-02-07 Impact factor: 4.818
Authors: Georg Dultz; Tobias Müller; Jörg Petersen; Stefan Mauss; Tim Zimmermann; Marion Muche; Karl-Georg Simon; Thomas Berg; Stefan Zeuzem; Dietrich Hüppe; Klaus Böker; Heiner Wedemeyer; Tania M Welzel Journal: Drugs Aging Date: 2018-09 Impact factor: 4.271